SCHEMBL19047889

SCHEMBL19047889

NC1CCN(CCNc2ccc(N3CCOCC3)cc2)CC1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM1A O60341 5/20 0.59
▸ GAA P10253 4/20 0.46
▸ MAPT P10636 4/20 0.46
▸ RAB9A P51151 3/20 0.46
▸ ALOX12 P18054 3/20 0.46
▸ L3MBTL1 Q9Y468 3/20 0.46
▸ KDM4E B2RXH2 3/20 0.46
▸ NPC1 O15118 2/20 0.46
▸ HTT P42858 2/20 0.46
▸ ALDH1A1 P00352 4/20 0.44
▸ ALOX15 P16050 2/20 0.44
▸ SMN1; SMN2 Q16637 2/20 0.44
▸ TP53 P04637 1/20 0.44
▸ NPSR1 Q6W5P4 1/20 0.44
▸ RPS6KA3 P51812 1/20 0.43
▸ RPS6KA2 Q15349 1/20 0.43
▸ MAPK1 P28482 1/20 0.43
▸ TDP1 Q9NUW8 1/20 0.43
▸ LMNA P02545 1/20 0.42
▸ HRH3 Q9Y5N1 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19047887 0.88 KDM1A (0.58) KDM1AGAAMAPTL3MBTL1KDM4E
SCHEMBL19047974 0.86 KDM1A (0.59) KDM1AGAAMAPTKDM4EALDH1A1
SCHEMBL19047900 0.82 KDM1A (0.64) KDM1A
SCHEMBL19048065 0.79 KDM1A (0.63) KDM1A
SCHEMBL20134666 0.78 KDM1A (0.57) KDM1AMAPTALDH1A1HRH3
SCHEMBL13438615 0.78 JAK2 (0.48) KDM1AGAAMAPTRAB9AALOX12
SCHEMBL11934725 0.78 JAK2 (0.48) KDM1AGAAMAPTRAB9AALOX12
SCHEMBL13438623 0.78 JAK2 (0.48) KDM1AGAAMAPTRAB9AALOX12
SCHEMBL19047885 0.77 KDM1A (0.64) KDM1A
SCHEMBL23775470 0.76 HRH3 (0.53) MAPTL3MBTL1SMN1; SMN2HRH3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3397616-B1 LSD1 INHIBITORS MIRATI THERAPEUTICS INC (US) 2020-06-10 — — EP disclosed
US-9809541-B2 LSD1 inhibitors Mirati Therapeutics, Inc. (US) 2017-11-07 — — US disclosed
US-20170183308-A1 LSD1 Inhibitors Mirati Therapeutics, Inc. (US) 2017-06-29 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170183308-A1 LSD1 Inhibitors KDM1B, KDM1A, KDM3A KDM1A 2/4885GAA 910/4885MAPT 1949/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback